Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat, administered on two schedules: three times a week every week or every other week on a 28-day treatment cycle in patients with advanced hematologic malignancies. The criteria for hematologic dose-limiting toxicities differed between patients with indications associated with severe cytopenias at baseline (leukemia and myeloid disorders) and those less commonly associated with baseline cytopenias (lymphoma and myeloma). In patients with leukemia and myeloid disorders, 60 mg was the MTD for weekly as well as biweekly panobinostat. In patients with lymphoma and myeloma, 40 mg was the recommended dose for phase II evaluation (formal MTD not determined) of weekly panobinostat, and 60 mg was the MTD for biweekly panobinostat. Overall, panobinostat-related grade 3-4 adverse events included thrombocytopenia (41.5%), fatigue (21%) and neutropenia (21%). Single-agent activity was observed in several indications, including Hodgkin lymphoma and myelofibrosis. This phase Ia/II study provided a broad analysis of the safety profile and efficacy of single-agent panobinostat in patients with hematologic malignancies.
INTRODUCTION
Acetylation is a common and reversible post-translational protein modification. 1 A recent study identified 1750 proteins as targets for acetylation, and proteins regulated by acetylation are implicated in carcinogenesis. 1 This diverse group of proteins is involved in a variety of cellular functions and includes histones, the protein chaperone Hsp90, the tumor suppressor p53, the proangiogenic transcription factor Hif1-a and the cytoskeletal protein a-tubulin. 2, 3 Acetylation is regulated by the activity of histone acetyltransferases, whereas deacetylation is mediated by the histone deacetylase (HDAC) class of enzymes. 2, 3 There are 11 HDAC enzymes (excluding class III NAD þ -dependent sirtuins) across three classes (class I, II and IV), which differ in intracellular localization and target proteins. 2, 3 Dysregulation of these enzymes leads to altered acetylation of cellular proteins, and global hypoacetylation of histone proteins has been identified as a hallmark of cancer development. 4 Deacetylase inhibitors (DACi) are a novel class of anticancer agents. Currently, two DACi, vorinostat and romidepsin, are approved by the US Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. 5, 6 DACi lead to hyperacetylation of target proteins and elicit anticancer activity through induction of cell-cycle arrest, apoptosis, differentiation and targeting of the tumor microenvironment. 2 Panobinostat is a potent pan-DACi with greater inhibitory activity of HDACs than currently approved agents. [7] [8] [9] [10] [11] [12] [13] [14] Preclinical studies have shown that panobinostat has antitumor activity against hematologic tumors, including Hodgkin lymphoma (HL) and multiple myeloma (MM) cells. 14, 15 In patients, panobinostat has been shown to elicit direct epigenetic effects, including induction of fetal hemoglobin. 16 On the basis of promising preclinical activity, this phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of single-agent panobinostat on two different dosing schedules in patients with hematologic malignancies. The study was designed to determine the differences between a weekly schedule, in which the increased frequency had the potential to lead to higher potency, and a biweekly schedule, in which intermittent dosing had the potential to result in a more tolerable safety profile and allow for greater therapy duration. Overall, the trial was conducted to gain insight on the safety, pharmacokinetics (PK) and preliminary activity of panobinostat in hematologic malignancies to better understand the patient population that may benefit.
MATERIALS AND METHODS Patients
Adult patients with advanced hematologic malignancies whose disease had progressed on or following available standard treatments or for whom no standard therapy existed were eligible. All patients were required to have a World Health Organization performance score p2 and adequate hepatic and renal function. Patients were excluded if they had active central nervous system disease, impaired cardiac function or other severe or uncontrollable medical conditions. Patients who received prior DACi treatment for cancer or who were receiving active treatment with agents with the potential to prolong QT interval were also excluded. This study was conducted according to the guidelines of the Declaration of Helsinki, and written informed consent was obtained from all patients. The study and amendments were reviewed by the independent ethics committee or institutional review board for each center.
Study design and patient enrollment
The primary objective of this two-arm, open-label, multicenter, phase Ia/II study was to determine the MTD of panobinostat on two different schedules. The study design is outlined in Figure 1 . In the dose-escalation phase, panobinostat was administered during 28-day treatment cycles according to one of two dosing schedules: once a day three days per week every week (Arm 1) or every other week (Arm 2). The starting doses were 20 mg for Arm 1 and 30 mg for Arm 2. The criteria for hematologic doselimiting toxicities (DLTs) differed between patients with indications associated with disease-related cytopenias-Group X: acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myelofibrosis (MF), acute lymphoblastic leukemia, chronic myelomonocytic leukemia, chronic myeloid leukemia (CML), atypical CML, chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia-and patients with indications not typically associated with disease-related cytopenias-Group Y: MM HL, and nonHodgkin lymphoma (NHL). Dose escalation and determination of the MTD were guided by a three-parameter Bayesian logistic regression model with overdose control similar to that proposed by Babb et al. 17 Each arm enrolled independently so that during dose escalation neither subarm 1X/ 2X nor 1Y/2Y will be 41 treated dose level ahead of the other. In the doseescalation phase, 53 patients were enrolled in Arm 1 Group X and 26 in Arm 1 Group Y. Of patients enrolled in Arm 2, 33 were enrolled in Group X and 23 in Group Y. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v.3.0). Following MTD determination, an additional 41 patients were evaluated for safety and efficacy in the dose-expansion phase.
Hematologic DLT criteria for Group X indications (myeloid malignancies) were defined as the inability to administer panobinostat for 442 days after the first missed dose because of grade 4 neutropenia or thrombocytopenia that was unrelated to disease. For patients with Group Y indications (lymphoid malignancies), hematologic DLT was defined as grade 4 neutropenia for 47 consecutive days, grade 4 thrombocytopenia or febrile neutropenia (absolute neutrophil count o0.5 Â 10 9 /l, fever X38.5 1C). Non-hematologic DLT criteria were identical for both groups and included renal impairment (Xgrade 3 serum creatinine or X2.0 Â upper limit of normal for 47 consecutive days), hepatic impairment (Xgrade 3 total bilirubin or X2.0 Â upper limit of normal to p3.0 Â upper limit of normal for 47 consecutive days; grade 3 aspartate aminotransferase or alanine aminotransferase for 47 consecutive days or grade 4), cardiac abnormalities (Xgrade 3) and neurotoxicity (41 grade increase). Additional DLTs included grade 3 adverse events (AEs) (excluding grade 3 elevations in alkaline phosphatase) that interfered with the ability to administer panobinostat for 47 consecutive days, grade 4 AEs (excluding grade 4 elevations in alkaline phosphatase), Xgrade 3 vomiting, grade 3 nausea despite the use of antiemetics, Xgrade 3 diarrhea despite the use of antidiarrheal medications and any AE that interfered with the ability to administer 47 doses (Arm 1) or 44 doses (Arm 2) of panobinostat within a cycle of treatment. The study further evaluated patients with AML and a group of patients with various hematologic malignancies (acute lymphoblastic leukemia, MDS, MF, chronic myelomonocytic leukemia, atypical CML, CLL, prolymphocytic leukemia, HL and NHL) at the MTD for the weekly dosing schedule.
Safety assessments
Safety evaluations included assessment of hematologic parameters, biochemistry panel assessment, urinalysis and thyroid function test. Incidence of AEs was summarized by system organ class, severity, type and relation to study drug. Comprehensive cardiac assessments were performed, including electrocardiograms at baseline, throughout treatment and at the end of treatment, as well as cardiac enzyme assessment at baseline, on day 8 of cycles 1 and 2, as clinically indicated during treatment, and at the end of treatment. A multigated acquisition scan and/ or an echocardiogram was also performed at baseline and end of treatment.
Efficacy assessments
For patients with AML, responses were based on the criteria outlined by Cheson et al. 18 Assessment of response in patients with MF was based on Tefferi et al, 19 including physical examination of spleen size, assessment of constitutional symptoms and complete blood count with differential. The response criteria for HL were based on Cheson et al. 20 A computed tomography (CT) scan was performed at baseline and repeated for determination of anatomic response p7 days before the completion of each even-numbered cycle, at the end of treatment and as determined necessary by the investigator. An exploratory analysis of metabolic response using [ 18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) was also performed in patients with HL. A standardized imaging protocol was used per institutional guidelines at each site. FDG-PET data were evaluated using modified European Organization for Research and Treatment of Cancer criteria, 21 with thresholds for progression and response set at ± 25% change in standardized uptake value versus baseline rather than ± 20%. Analysis of response for HL patients was conducted by the investigator and also by central review (VirtualScopics, Inc., Rochester, NY, USA).
PK and pharmacodynamics
The methodology for panobinostat PK and pharmacodynamic analysis of histone acetylation are described in the Supplementary Material.
Statistical analysis
The MTD determination and toxicity monitoring during the doseescalation phase of the trial were based on a three-parameter version of a Bayesian logistic regression model with overdose control. 17 Separate but identical models were used for each X and Y group and were updated after Figure 1 . Study design and patient enrollment. Patients with various hematologic malignancies were enrolled into the dose-escalation phase of the trial and administered panobinostat three times weekly (that is, Monday, Wednesday and Friday) every week or three times weekly every other week. The starting dose for weekly panobinostat was 20 mg, and 30 mg was the starting dose for every other week dosing. Panobinostat was evaluated at escalating doses until the MTD was determined. The criteria for DLTs differed between the patient groups (X and Y). Additional patients were evaluated in the dose-expansion phase for the assessment of safety and activity of weekly panobinostat only. Patients with MM or chronic myelogenous leukemia were not evaluated in the dose-expansion phase. aCML, atypical CML; ALL, acute lymphocytic leukemia; CMML, chronic myelomonocytic leukemia; MWF, Monday, Wednesday and Friday.
each cohort of patients had completed enrollment and a first cycle of treatment. Selection of subsequent doses was based on these probabilities along with clinical information.
RESULTS

Patients and treatment
From 6 March 2006 to 2 December 2009, 176 patients were enrolled in the study. There were 119 patients enrolled with Group X indications (myeloid malignancies); 86 patients received panobinostat three times weekly every week (Arm 1), and 33 patients received panobinostat every other week (Arm 2; Table 1 ). The most common indication in Group X was AML (n ¼ 83, 69.7% overall). In all, 57 patients with Group Y indications (lymphoid malignancies) were enrolled in the trial, with 34 patients on Arm 1 and 23 on Arm 2. Patients with HL accounted for 18.2% (n ¼ 32) of patients enrolled in the study. The median age of the overall patient population was 63 years, and was higher among Group X patients compared with Group Y patients, which is generally reflective of patients enrolled in these groups (AML vs HL).
Dose escalation and determination of MTD Because of disease-related cytopenias, hematologic DLT criteria differed between Group X and Group Y (see Methods). For Arm 1 Group X patients, the MTD dose was determined to be 60 mg. The most common DLT observed in Arm 1 Group X was fatigue, which was observed in five patients across doses of 40-80 mg (Table 2) . Cardiac-related DLTs were observed at 80 mg in three patients, including two instances of grade 3 QTcF prolongation. Among Group X patients who received panobinostat three times weekly every other week (Arm 2), DLTs were observed at the dose of 80 mg. The most common DLTs included cardiac-related AEs and fatigue (Table 2) . Although it was determined that 80 mg exceeded the MTD, further evaluation at the 60-mg biweekly dosing was not conducted because preliminary efficacy was more promising for the weekly dosing schedule. Thus, the sample size was not sufficient for the MTD to be formally determined per protocol, and 60 mg was considered to be the highest safe dose evaluated.
Thrombocytopenia was a DLT in nine Arm 1 Group Y patients treated at the 40-and 60-mg doses. On the basis of DLT information from patients treated at different cohorts in Arm 1 Group Y, Bayesian logistic regression analysis indicated 38 mg of panobinostat to be the highest recommended dose for a new cohort. However, as the smallest capsule strength was 5 mg, and the DLT of thrombocytopenia observed was deemed to be acceptable for this patient population, the investigators decided that 40 mg could be further evaluated. This dose was formally declared to be the recommended phase II dose rather than the MTD. For Arm 2 Group Y patients, DLTs were observed in three patients at the 60-mg dose, and thrombocytopenia occurred in two of three patients (Table 2) , 60 mg was declared to be the MTD.
Safety
All 176 patients had discontinued at the time of the final data analysis, most commonly due to disease progression (56.3%). An additional 45 patients (25.6%) discontinued because of AEs. A total of 42 deaths occurred while on study treatment or within 28 days of the last panobinostat dose. Death was the reason for discontinuation for eight patients (4.5%). Two of these deaths were suspected to be related to panobinostat and occurred in Arm 1 Group X patients. One death was due to pulmonary hemorrhage secondary to bronchopulmonary aspergillosis at 60 mg, and another was due to multiorgan failure in a patient who experienced acute renal failure and sepsis at 80 mg.
Common AEs suspected to be treatment related are summarized in Table 3 . AEs regardless of relation to study drug are summarized in Supplementary Data 1 and 2. Overall, the most common AEs suspected to be treatment related were gastrointestinal and hematologic in nature. Most gastrointestinal AEs were mild (grades 1 and 2). Common hematologic AEs related to study drug included thrombocytopenia, neutropenia and anemia. As observed in other studies with panobinostat, 22, 23 thrombocytopenia was the most common grade 3-4 AE and was more common in patients with Group Y indications. Although Panobinostat in hematologic malignancies DJ DeAngelo et al the incidence of thrombocytopenia was relatively high, discontinuation due to thrombocytopenia was rare (four patients, 2.3%), as thrombocytopenia was reversible and manageable following dose delays and interruptions. The time to onset and duration of grade 3-4 thrombocytopenia analysis was conducted using Kaplan-Meier method on platelet count data (Supplementary Data 3). For Arm 1 the median time to grade 3-4 thrombocytopenia for Groups X and Y was 12 and 15 days, respectively; median duration was 10 and 4 days, respectively. For Arm 2 the median time to grade 3-4 thrombocytopenia for Groups X and Y was 12 and 64 days, respectively; median duration was 38 and 4 days, respectively. Although differences were observed among the arms and groups, the ability to draw conclusions is confounded by the various dose groups within each arm and other factors, including dose reductions and blood transfusions. Fatigue, another common AE related to panobinostat, was observed in 53% of patients overall with a grade 3-4 incidence of 21%. Because of small patient numbers among dose cohorts, no clear The treated patients who were not evaluable for the MTD-determining population received o9 doses (Arm 1) or o5 doses (Arm 2) during cycle 1 and did not experience any DLTs during cycle 1. 
Efficacy in Hodgkin lymphoma
Intriguing preliminary activity was noted in an earlier report of 13 patients with HL enrolled in this trial. 24 The characteristics of all 32 patients with HL are summarized in Table 4 . Patients were heavily pretreated with a median of five (range 3-16) prior therapeutic regimens. Patient profile review demonstrated that all patients received prior autologous stem cell transplant, and 13 patients received prior allogeneic stem cell transplantation. Response was evaluated by investigator assessment and central review. Best response for all patients by CT and FDG-PET is presented in Table 5 . Activity of panobinostat was demonstrated in these heavily pretreated patients. Anatomic response rate, as determined by central review, was 34.4% (11 partial response (PR)), and metabolic response rate, by FDG-PET central review, was 53.1%. Waterfall plots demonstrating best metabolic and anatomic responses by central review are shown in Figures 2a and b, respectively. Responses to panobinostat in patients with HL were durable. Response data were available for patients assessed by CT according to investigator assessment (n ¼ 9). Patient profile review of duration of response demonstrated a median of 283 days (range 1-309; n ¼ 7 censored because of missing evaluations, including loss to follow-up, or no documentation of PD), with four patients demonstrating duration of response 4150 days. Of four patients who demonstrated long-term responses, two started treatment at the planned dose of 40 mg in Arm 1 (phase 2 recommended dose) and were subsequently dose reduced to 20 mg, the third patient received a starting dose of 60 mg (in Arm 2) and was dose reduced to 20 mg and the fourth patient received a starting dose of 30 mg in Arm 1 with no subsequent dose reductions. These data, combined with low rates of progressive disease (one patient by CT, four patients by FDG-PET), support activity of panobinostat in relapsed HL and suggest that lower doses may be preferred for long-term treatment.
Efficacy in MF In all, 13 patients with MF were treated on this trial (Table 6) 25 This patient maintained a complete cytogenetic response for 412 months. The other patient with AML with multilineage dysplasia following MDS with normal cytogenetics demonstrated a CR for 50 days. Number of cycles on treatment, n (%) p1 1 (7. Although patient numbers were limited, activity was observed in other indications. Nine patients with MDS were treated on Arm 1, and two were treated on Arm 2. Modest activity was observed, with one PR observed in an Arm 2 patient with a chromosome 20q deletion treated with 60 mg panobinostat. Stable disease was observed in four patients treated in Arm 1 and one patient in Arm 2. Review of the patient profiles among the other indications demonstrated a PR in one patient with MM, one patient with CLL, two patients with NHL, including one patient with diffuse small lymphocytic B-cell lymphoma and one patient with pleomorphic T-cell lymphoma of the skin.
DISCUSSION
This phase Ia/II study provided a comprehensive overview of the safety, PK and activity of panobinostat in a wide range of hematologic malignancies. A dose of 60 mg was determined to be the MTD in Group X patients in Arms 1 and 2 and Group Y patients in Arm 2. For Group Y patients treated on the weekly schedule (Arm 1), 60 mg exceeded MTD, and 40 mg of panobinostat was the recommended dose for phase II. Overall, the MTD of panobinostat differed based on the patient indication and schedule of administration. Of note, the 40-mg weekly dose was evaluated in a phase II trial of patients with relapsed/refractory HL, and the phase II/III PANORAMA program in MM is evaluating panobinostat in combination with bortezomib and dexamethasone using a 20-mg dose administered three times weekly for 2 weeks followed by a 1-week treatment holiday. 22, 23, 26 As investigation of panobinostat in other hematologic malignancies continues, the dose and schedule will need to be tailored for each indication and combination partner.
Overall, safety data were similar to other studies of DACi, with nausea, diarrhea and fatigue as the most common study drugrelated non-hematologic AEs. 22, 23, 27, 28 The most common grade 3-4 AEs related to panobinostat were hematologic, and thrombocytopenia was the most common grade 3-4 AE observed. Thrombocytopenia is commonly observed in trials with panobinostat but is rapidly reversible and manageable with dose interruptions or reductions and rarely lead to treatment discontinuations or hemorrhages. Recent preclinical studies demonstrated that panobinostat-related thrombocytopenia is transient and rapidly reversible upon drug removal 29 and inhibits platelet budding by leading to increased phosphorylation of the myosin light chains. 30 PK parameters, including C max , AUC and t 1/2 , were similar to those observed in other studies of panobinostat. 31 C max and AUC increased near dose proportionally through 50 mg. In addition, minimal drug accumulation was observed following thrice-weekly dosing, and sustained histone acetylation was observed in a majority of patient blood samples, particularly at doses above 20 mg, suggesting prolonged intracellular effects. Owing to low sensitivity of the western blot assay and limited single-agent efficacy, a clear correlation for acetylation was not observed. Future studies should analyze the correlation between global protein acetylation status with efficacy and/or toxicity.
The antitumor activity of single-agent panobinostat was most apparent in patients with HL. Central review analysis demonstrated a response rate by CT of 34.4% and a response rate by FDG-PET of 53.1%. These data led to further investigation in a phase II trial of panobinostat in patients with HL after autologous stem cell transplant. These recent data confirm the activity observed here, with a 27% overall response rate by CT, including five CRs per investigator assessment. 23 CI was noted in four of 13 patients with MF. Mutation of JAK2 was confirmed in three of the four patients demonstrating CI. Although three of the patients demonstrating CI were treated with 60 mg of panobinostat, all of these patients had dose reductions, and preliminary reports from recent studies seem to suggest that a lower dose (o40 mg) may allow for longer therapy duration. 32, 33 Clinical trial experience with panobinostat has demonstrated longterm tolerability (ongoing 42 years) and remarkable clinical benefit in patients who received panobinostat at 25-30 mg, three times per week, every other week (Kavita Natrajan, personal communication). Furthermore, a recent study with another panDACi, givinostat, demonstrated clinical responses in patients with JAK2V617F-positive myeloproliferative neoplasms, including MF. 34 Mechanistically, it has been demonstrated that panobinostat inhibits JAK2V617F signaling and depletes mutant JAK2V617F protein via inhibition of Hsp90 activity. 35 Indeed, both panobinostat and the Hsp90 inhibitor AUY922 synergistically activate apoptosis of myeloproliferative neoplastic cells when used in combination with JAK inhibitors. 35, 36 On the basis of these findings, a phase I study of combination panobinostat and the JAK1/2 inhibitor ruxolitinib is ongoing in patients with MF.
Although not as striking, some intriguing results were noted in other indications. Cytogenetic analysis identified that one patient who achieved CR had a translocation of MLL and CREB binding protein: t(11;16)(q23;p13.3). MLL is a transcriptional regulator implicated in HDAC-dependent epigenetic pathways, and MLL genetic aberrations, including translocations, have been implicated in leukemogenesis. 37, 38 The observation of a CR in a patient with MLL-aberrant leukemia is worth noting as panobinostat targets both epigenetic and non-epigenetic pathways, and further clinical investigation is warranted. 25 In addition, a separate report of a patient treated on this study demonstrated laboratory tumor lysis syndrome in a patient with AML with cytogenetically determined trisomy 8 and del(20q). Substantial decreases of white blood cell counts (60 Â 10 9 /l to 6 Â 10 9 /l) were observed within 24 h of panobinostat administration. 39 These data supported the antileukemic activity of panobinostat, and also provide cautionary evidence for the potential of tumor lysis. A PR was also observed in a patient with MDS with del(20q). Further analysis may identify genetic aberrations associated with the activity of panobinostat in patients with AML and MDS, and current trials are evaluating panobinostat in combination with standard-of-care agents that have demonstrated synergy in preclinical models, including anthracylines and demethylating agents. [40] [41] [42] [43] Modest activity in MM was demonstrated with one PR observed. Further investigation of panobinostat in MM will most likely be as a combination therapy based on preclinical evidence, demonstrating that dual inhibition of the proteasome and aggresome by bortezomib and panobinostat, respectively, leads to MM cell death. 44, 45 Recent results from three separate phase I clinical trials of panobinostat, vorinostat or romidepsin in combination with the proteasome inhibitor bortezomib demonstrated encouraging activity in patients with relapsed and refractory MM, including PR in patients with bortezomib-refractory MM. 22, 46, 47 Preliminary reports from phase II and III studies are suggesting that combination therapy with DACi can overcome resistance to bortezomib therapy in patients with relapsed/refractory MM. 26, [48] [49] [50] DACi are well known to be effective in patients with cutaneous T-cell lymphoma and peripheral T-cell lymphoma. 28, [51] [52] [53] Moreover, a recent trial evaluating vorinostat in patients with NHL demonstrated encouraging activity, including a response rate of 47% (four CR, four PR) among patients with follicular lymphoma. 54 In the study reported here, only 13 patients with NHL were enrolled, and two PR were observed in one patient with diffuse small lymphocytic B-cell lymphoma and one patient with pleomorphic T-cell lymphoma of the skin, as determined by patient profile review. On the basis of these observations, future studies should evaluate panobinostat in a larger cohort of patients with NHL subtypes that are associated with response to DACi.
This study represented the first phase I trial that evaluated panobinostat in a broad range of hematologic malignancies and established the efficacy, safety and PK profile for this potent DACi.
Promising single-agent activity was noted in patients with relapsed and refractory HL, and MF, and led to the design of phase II trials in these indications. 23, 33 Of note, although the MTD was identified, a majority of patients who received long-term panobinostat had at least one dose reduction. These data seem to suggest that doses lower than the MTD may have higher longterm tolerability. Along with elucidation of the safety profile, these data guided the design of subsequent trials in indications, such as MM and MDS, in which panobinostat holds promise as a combination therapy. 26, 41, 49 For these studies, panobinostat is administered at doses lower than the MTD identified in this study, and treatment holidays are included in the dosing schedules. Ongoing and future studies will seek to optimize the dose and schedule of panobinostat with combination partners across various hematologic malignancies.
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